Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities

OBJECTIVE: Pharmacological inhibition of the renin-angiotensin-aldosterone-system (RAASi) is the cornerstone of hypertension treatment, renoprotection and secondary prevention of cardiovascular disease in patients with type 2 diabetes. Although there is a dose-dependent effect of RAASi with optimum...

Descripción completa

Detalles Bibliográficos
Autores principales: Gant, C. M., Oosterwijk, M. M., Binnenmars, S. H., Navis, G. J., Haverkate, H., Bakker, S. J. L., Laverman, G. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428595/
https://www.ncbi.nlm.nih.gov/pubmed/37587437
http://dx.doi.org/10.1186/s12882-023-03205-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428595/
https://www.ncbi.nlm.nih.gov/pubmed/37587437
http://dx.doi.org/10.1186/s12882-023-03205-2

Ejemplares similares